Navigation Links
Actinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
Date:9/18/2013

NEW YORK, Sept. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Corey Sohmer to the position of Vice President of Finance and Business Development.  Mr. Sohmer will be responsible for directing Actinium's accounting, finance and investor relations functions as well as supporting capital raising and business development activities.

"Corey has a broad financial background in the biotech industry. He brings leadership experience relevant to all key aspects of Actinium's corporate development, including financing, accounting, investor relations and public reporting," said Kaushik J. Dave, Ph.D., MBA, President and CEO of Actinium.  "Corey will be an extremely valuable addition to the Actinium team as we continue to progress the Company's lead candidates Iomab-B and Actimab-A."

"I am excited to join the Company at a pivotal point in its growth and look forward to contributing to its future success," said Mr. Sohmer.  Prior to joining Actinium, Mr. Sohmer served in a variety of core finance and business development functions over the span of twelve years at three NASDAQ listed biopharmaceutical companies.  Most recently, Mr. Sohmer was the Director Corporate Finance at Cyclacel Pharmaceuticals, Inc. for six years.   Before joining Cyclacel, he was the Senior Director of Financial Planning and External Reporting at EpiCept Corporation and Manager of Finance and Business Development at Pharmos Corporation.  He has more than 20 years of finance and accounting experience.  Mr. Sohmer holds a Masters in Business Administration and a Bachelors of Science degree in Accounting from Bentley University.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:
Visit our web site www.actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr.
Tel:  (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com

Contact:
Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
E-mail: ir@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
2. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
3. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
4. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
5. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
8. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
9. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... a pilot study of ActiGraph’s CentrePoint Data Hub in a sample ... provider of clinical-grade wearable activity and sleep monitoring solutions for the global scientific ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that has ... presence to an educational purpose as the host of the “Informed” series. The program ... a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to meet ... reject an outdated healthcare executive resume. , “If you’re a healthcare executive open to ... and wondering if it’s as ready as you are for a new job search. ...
(Date:4/27/2017)... ... 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today ... , The first new location will open at the corner of 27th and ... Northern Lights Drive this fall. And the third location is in the process of ...
Breaking Medicine News(10 mins):